Actively Recruiting
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Led by Bristol-Myers Squibb · Updated on 2026-03-17
184
Participants Needed
19
Research Sites
173 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.
CONDITIONS
Official Title
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- For healthy volunteers (Cohort A): Adults who are healthy males or females not of childbearing potential, with BMI between 18.0 and 32.0 kg/m², and no significant organ dysfunction or abnormal clinical findings.
- For sickle cell disease participants (Cohort B): Adults diagnosed with Sickle Cell Disease (HbSS, HbSβ0-thalassemia, or HbSβ+-thalassemia), with at least 4 vaso-occlusive crises in the past year or 2 in the past 6 months.
- ECOG performance status of 0 or 1.
- Laboratory values including hemoglobin between 5.5 and 12 g/dL for males or 5.5 and 10.6 g/dL for females, neutrophil count ≥1500/μL, platelet count ≥100,000/μL, and reticulocyte count >100,000/μL or >50,000/μL if taking hydroxyurea.
You will not qualify if you...
- For healthy volunteers (Cohort A): Any significant medical condition or laboratory abnormality that risks data interpretation or participant safety.
- Major or planned surgery (except gastrointestinal) within 12 weeks before treatment.
- For sickle cell disease participants (Cohort B): Any significant acute or chronic illness, active or uncontrolled infection, or lab abnormalities posing risk.
- More than 6 severe vaso-occlusive crises requiring hospital stays over 24 hours in the past year, or any such crisis in the last 30 days.
- Acute chest syndrome within 6 months before treatment.
- Creatinine clearance below 60 mL/min/1.72m².
- Regularly scheduled red blood cell or platelet transfusions or recent transfusions within 28 days (RBC) or 14 days (platelet) before starting BMS-986470.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 19 locations
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
Actively Recruiting
2
University of California San Diego - La Jolla
La Jolla, California, United States, 92037
Actively Recruiting
3
UCSF Benioff Children's Hospital Oakland
Oakland, California, United States, 94609
Actively Recruiting
4
Yale-New Haven Hospital
New Haven, Connecticut, United States, 06510
Actively Recruiting
5
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States, 30322
Actively Recruiting
6
Local Institution - 0034
Chicago, Illinois, United States, 60612
Not Yet Recruiting
7
Local Institution - 0001
Lenexa, Kansas, United States, 66219
Active, Not Recruiting
8
Local Institution - 0024
Boston, Massachusetts, United States, 02114
Not Yet Recruiting
9
Boston Medical Center
Boston, Massachusetts, United States, 02118
Actively Recruiting
10
Thomas Jefferson University - Medicine/GI and Hepatology
Philadelphia, Pennsylvania, United States, 19107
Actively Recruiting
11
Local Institution - 0032
Pittsburgh, Pennsylvania, United States, 15213
Not Yet Recruiting
12
Inova Schar Cancer Institute
Fairfax, Virginia, United States, 22031
Actively Recruiting
13
Virginia Commonwealth University (VCU) Medical Center
Richmond, Virginia, United States, 23298
Actively Recruiting
14
Institut de cancérologie Strasbourg Europe (ICANS)
Strasbourg, Alsace, France, 67033
Actively Recruiting
15
Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone
Marseille, France, 13385
Actively Recruiting
16
Hôpital Universitaire Necker Enfants Malades
Paris, France, 75015
Actively Recruiting
17
University Hospitals Sussex NHS Foundation Trust
East Sussex, Brighton And Hove, United Kingdom, BN2 1ES
Actively Recruiting
18
King's College Hospital
London, London, City of, United Kingdom, SE5 9RL
Actively Recruiting
19
Local Institution - 0005
Leeds, United Kingdom, LS9 7TF
Not Yet Recruiting
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
F
First line of the email MUST contain NCT # and Site #.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here